Thursday, Abbott Laboratories (NYSE:ABT) said it is recalling some FreeStyle Libre 3 sensors after finding that a small ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Abbott has received an innovation award for Lingo, its first consumer biowearable over-the-counter device designed to support ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...

system to people with diabetes in Europe that will monitor blood glucose levels and deliver insulin automatically. The three-way partnership brings Abbott's FreeStyle Libre 3 wearable sensor with ...

Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device that helps people ...

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their continuous glucose monitors for people with diabetes—just weeks after a ...

Abbott's Medical (TASE: PMCN) Devices segment was a bright spot, with sales rising 13.7% to $5.05 billion in Q4. The Diabetes ...